SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

DNLI

Denali Therapeutics Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed13d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor Q4 2026 AVLAYAH revenue against the $30.0M-$32.0M guidance to gauge commercial trajectory. Key pipeline catalysts in 2027 include zafinofusp alfa BLA submission, DNL593 Phase 1/2 data, and DNL628/DNL921/DNL952 initial data.

DirectionNeutral
Confidencehigh
Horizonmonths

tividenofusp alfa-eknm

● Neutral Named in this press release
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
Next catalyst
None dated

What to watchThe next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$20.96
T+0 close · Nov 3, 2026 · via day close
Latest settled
−5.87%
T+5 · $19.73 · next T+20 in 16d
Vs SPY
−4.96%
α at T+5
Latest observation
−9.72%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $20.96entry
  2. T+1 · 12d ago −5.92%α −1.51% · $19.72
  3. T+5 · 6d ago −5.87%α −4.96% · $19.73
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics reported Q3 2026 AVLAYAH net product revenue of $17.8M, its second full commercial quarter, and guided Q4 2026 revenue to $30.0M-$32.0M. Net income of $70.1M included a one-time $194.0M gain on sale of a Priority Review Voucher, while operating loss was $126.8M. Cash and securities totaled $1.0B.

Key Financial Metrics

EPS
$0.37
Revenue
$17.8M
est $22.9M · -22.4%
Guidance
$30.0M-$32.0M
initiated

Key Facts

  • AVLAYAH net product revenue $17.8M in Q3 2026 (second full commercial quarter).
  • Q4 2026 net product revenue guidance of $30.0M-$32.0M.
  • Net income $70.1M vs net loss $126.9M in Q3 2025; includes $194.0M one-time gain on sale of Priority Review Voucher.
  • Operating loss $126.8M vs $137.4M in Q3 2025.
  • Cash, cash equivalents and marketable securities $1.0B as of September 30, 2026.
  • Payer coverage exceeded 70% of U.S. commercial lives, up from >50% in prior quarter.
  • BLA submission for zafinofusp alfa (Sanfilippo syndrome type A) on track for 2027 seeking accelerated approval.
  • Multiple pipeline programs expected to generate data in 2027.

Financial Impact

AVLAYAH revenue $17.8M in Q3, guided to $30.0M-$32.0M in Q4; operating loss $126.8M; one-time gain $194.0M; cash $1.0B.

revenueoperating losscash

Risk Factors

  • AVLAYAH revenue growth may not sustain at recent rates; quarterly variability expected.
  • Reliance on accelerated approval pathway for zafinofusp alfa; FDA may require additional studies.
  • Operating losses continue; cash burn rate depends on pipeline advancement and commercial costs.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394747

Track record

17 reports on DNLI

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Viewing Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026